The stock of Hims & Hers Health (HIMS) was up as much as 7% after the company announced that it has expanded its partnership with Eli Lilly (LLY).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Going forward, healthcare providers on the Hims & Hers platform will be able to prescribe Eli LiIly’s weight-loss medications. Hims & Hers is a telehealth company. Going forward, consumers will be able to get prescriptions for Eli Lilly’s Zepbound and its new weight-loss pill Foundayo filled on the platform.
The partnership expansion comes after Hims & Hers’ announcement last month of a collaboration with Novo Nordisk (NVO) to help customers access Wegovy injections and pills. Hims & Hers is trying to increase access to weight-loss drugs that are extremely popular with consumers.
Weight-Loss Pill Demand
Hims & Hers said its weight loss membership includes comprehensive support services, 24/7 direct access to a care team, personalized nutrition guidance, ongoing clinical check-ins, and peer support in the Hims & Hers Weight Loss community.
The company stated its goal is to provide customers with access to a diverse range of treatment options alongside a comprehensive care experience based on their unique history, preferences, needs, and goals.